LIVECAST Markets Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics News Archive Account

Home News ArchiveBank of England Orders Review of Revolut’s Product Approval Processes

Live News REGULATION FLASH M impact Oct 27, 2026, 05:02 AM UTC

Bank of England Orders Review of Revolut’s Product Approval Processes

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

South Korea's ruling party to launch probe into Supreme Court chief South Korea's ruling party concluded a lawmakers' meeting with a decision to conduct a parliamentary investigation into allegations involving Supreme Court Chief Justice Cho Hee-da M impact | REGULATION | Oct 27, 2026, 06:08 AM UTC FTC Sues Dollar General Over Deceptive Pricing Practices The FTC sued Dollar General, alleging it routinely charged customers more at checkout than prices displayed on shelves, tags and advertisements. Twenty states joined the complaint. M impact | REGULATION | Oct 27, 2026, 05:45 AM UTC Indian Defence Stocks Rally After DAC Clears ₹2.12 Lakh Crore Acquisitions Defence shares rallied after the Defence Acquisition Council cleared acquisition proposals worth ₹2.12 lakh crore for the armed forces. Apollo Micro Systems and Data Patterns led t M impact | REGULATION | Oct 27, 2026, 05:39 AM UTC Judge Suspends Trump Golf Course Project in Washington Indefinitely A federal judge suspended the project until further notice. L impact | REGULATION | Oct 27, 2026, 05:34 AM UTC Ingenia Therapeutics Gets FDA Clearance for IGT-303 Phase 1/2a Trial M impact | REGULATION | Oct 27, 2026, 05:34 AM UTC Ingenia Therapeutics Gets US Approval for IGT-303 Phase 1/2a Trial Ingenia Therapeutics received approval for the US clinical trial plan for IGT-303, a chronic kidney disease treatment. M impact | REGULATION | Oct 27, 2026, 05:34 AM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Macro
Politics
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.